CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

Natalizumab (Tysabri) and natalizumab biosimilar (Tyruko) coverage

Defines medical necessity, initial and continuation authorization, site-of-care rules, dosing references and specialty prescriber/REMS requirements for natalizumab (Tysabri) and natalizumab-sztn (Tyruko) for relapsing forms of MS and moderately to severely active Crohn's disease for Blue Cross NC members.

Policy Summary

PayerBlue Cross Blue Shield - North Carolina

PolicyNatalizumab (Tysabri) and natalizumab biosimilar (Tyruko) coverage

Policy CodePolicy N/A

Change TypeCriteria revised and added (Crohn's disease allowancebiosimilar addedcoding updates)

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and submit medical record documentation demonstrating diagnosis, symptom evidence and objective inflammation or prior biologic benefit as applicable.

SourceLink

POLICY UPDATE CHANGES

For CD: Added allowance for patients currently established on a biologic or systemic immunomodulator agent with demonstrated clinical benefit to qualify.

For CD: Replaced requirement of severely active disease with requirement to demonstrate moderately to severely active disease by specific symptom plus objective inflammation or other defined criteria.

Updated Site of Care medical necessity criteria to add additional bypasses for patients with history of severe adverse events or conditions increasing risk for severe adverse events.

Added natalizumab biosimilar Tyruko (natalizumab-sztn) with same FDA indications and coverage criteria as Tysabri.

Added HCPCS code Q5134 for Tyruko and removed nonspecific codes C9399/J3490/J3590.

2FDA indications

365Approval duration (days)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria

Initial Therapy - Multiple Sclerosis

Covered when ALL of the following are met

MS initial: 1. Diagnosis of a relapsing form of multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting, or active secondary progressive disease); AND

MS initial age and function: 2. Age ≥ 18 years; AND

MS initial functional status: 3. Patient retains ability to walk at least a few steps with or without aid OR has functional arm/hand use consistent with performing activities of daily living; AND

MS disease activity or prior therapy

Highly active disease: a. Highly active MS defined by BOTH: ≥2 relapses in the prior year; AND ONE of: ≥1 gadolinium‑enhancing lesion on MRI OR significant increase in T2 lesion load compared with prior MRI (medical record documentation required).
Prior therapy allowances: b. ONE of: trial and inadequate response to ONE listed generic MS agent (dimethyl fumarate, fingolimod, glatiramer acetate, teriflunomide) OR intolerance/hypersensitivity to one of these OR FDA‑labeled contraindication to ALL of these OR prior treatment with ≥3 MS agents from different drug classes (medical record documentation required).

Concurrent therapy exclusion: 5. Patient is NOT receiving concurrent therapy with two or more disease‑modifying MS drugs from the policy list (see policy for drug list).

Prescriber and program requirements: 6. Prescriber is a specialist for the diagnosis or has consulted a specialist; AND 7. Prescriber is registered through the MS TOUCH® or applicable REMS program.

Quantity and site of care: 8. Requested quantity does not exceed maximum units allowed for the duration of approval; AND 9. Site of care criteria applies for inpatient or outpatient infusion requests.

Initial Therapy - Crohn's Disease

Covered when ALL of the following are met

CD initial diagnosis: 1. Diagnosis of moderately to severely active Crohn's disease; AND

CD initial age: 2. Age ≥ 18 years; AND

CD disease activity or clinical context

Active inflammation: a. Moderately to severely active disease evidenced by symptoms consistent with active CD AND objective evidence of active inflammation on cross‑sectional imaging (MRE, CTE), intestinal ultrasound, or pelvic MRI for perianal disease; OR biomarker evidence (elevated fecal calprotectin, elevated CRP, elevated ESR, low serum albumin).
Significant extent/upper GI involvement: b. Significant extent of disease or upper GI involvement on radiographic or endoscopic assessment (e.g., large/deep mucosal lesions, fistulas, abscess, strictures, extensive disease such as ileal involvement >40 cm or pancolitis, prior bowel resection).

Continuation Therapy

Covered when ALL of the following are met

Continuation general: 1. Patient was approved through Blue Cross NC initial criteria OR would have met initial criteria at therapy start; AND

Clinical benefit: 2. Patient has demonstrated clinical benefit while receiving treatment (disease stability and/or improvement); AND

Continuation concurrent therapy rules: 3. ONE of the following: a. For MS: patient is NOT receiving concurrent therapy with two or more disease‑modifying MS drugs from the policy list; OR b. For CD: patient will NOT use the requested agent in combination with an immunomodulatory agent (e.g., TNF‑alpha inhibitors, JAK inhibitors, IL‑4 inhibitors).

Prescriber and program requirements continuation: 4. Prescriber is a specialist for the diagnosis or has consulted a specialist; AND 5. Prescriber is registered through the MS TOUCH® or CD TOUCH® or applicable REMS program; AND

The FDA label and policy explicitly state that natalizumab is not for use in combination with immunosuppressants or TNF-alpha inhibitors. This limitation applies to initiation and continuation of therapy and reflects the increased risk profile (including PML) described in the prescribing information. Clinical requests that document concurrent use with these agents do not meet the FDA-labeled limitations and are excluded from coverage under this policy.

The policy prohibits concurrent use with specified combination therapies. For multiple sclerosis, patients must not receive concurrent therapy with two or more disease-modifying MS drugs (the policy lists agents such as glatiramer, interferon betas, fingolimod, teriflunomide, dimethyl/monomethyl fumarate, ofatumumab, alemtuzumab, siponimod, cladribine, ocrelizumab, ponesimod, natalizumab [Tysabri, Tyruko], diroximel fumarate, ozanimod, ublituximab, and others). For Crohn’s disease, continuation and initiation criteria require that the patient will not use the requested agent in combination with an immunomodulatory agent (examples include TNF-alpha inhibitors, JAK inhibitors, IL-4 inhibitors) or other specified immunosuppressants. Requests proposing excluded concurrent therapies are not covered.

Dosing, Units, and Billing Codes

Covered HCPCS Codes (dosing references)HCPCSCovered

J2323	natalizumab (Tysabri) IV infusion (FDA label reference)
Q5134	natalizumab-sztn (Tyruko) IV infusion (FDA label reference)

Dose and interval — natalizumab

Dose and intervalIV: 300 mg every 4 weeks (300 mg q4w)

CD dosing noteFor Crohn's disease, discontinue if no therapeutic benefit by 12 weeks of induction and/or if unable to discontinue chronic concomitant steroids within 6 months

Pediatric/adult age referenceFDA label references include patients ≥18 years for relapsing MS and moderately to severely active CD

Maximum units — Tysabri and Tyruko

Maximum units (Tysabri)3900

Maximum units (Tyruko)3900

Prior Authorization, Documentation, and Denial Triggers

Prior Authorization

Prior Authorization Required

Prior authorization is required for the requested agent. Approval will be granted when the medical necessity criteria are met and required documentation is provided.

Prior authorization required and will be granted when ALL clinical criteria and documentation requirements are satisfied.
Affected HCPCS/J-codes: see billing/coding section of the policy for specific codes (prior authorization applies to those codes).

Step Therapy

Required Prior Therapy / Trials

Step therapy / prior agent requirements must be documented in the medical record. The patient must have tried and had an inadequate response, intolerance, hypersensitivity, or documented contraindication to specified prior MS agents unless they meet other high-activity or multi-agent treatment exceptions.

The patient has tried and had an inadequate response to ONE of: dimethyl fumarate (Tecfidera generic), fingolimod (Gilenya generic), glatiramer acetate (Copaxone or Glatopa generic), or teriflunomide (Aubagio generic), with documentation; OR

Key Definitions and Indication Details

Relapsing forms of MS / dosing

DefinitionRelapsing forms of MS include clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease.

DosingIV administration: 300 mg every 4 weeks (per FDA label).

Risk considerationNatalizumab increases risk of progressive multifocal leukoencephalopathy (PML); benefit–risk should be considered when initiating and continuing therapy.

Moderately to severely active Crohn's disease — definition

Core definitionModerately to severely active Crohn's disease: clinical symptoms consistent with active CD plus objective evidence of active inflammation on cross-sectional imaging, intestinal ultrasound, pelvic MRI for perianal disease, or biomarker evidence (e.g., elevated fecal calprotectin, CRP, ESR, low albumin).

Alternate criteria

Clinical Background

Natalizumab (Tysabri) and the natalizumab biosimilar Tyruko (natalizumab-sztn) are monoclonal antibodies indicated as monotherapy for adults with relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease) and for the induction and maintenance of clinical response and remission in adults with moderately to severely active Crohn’s disease with evidence of inflammation. The drug is administered intravenously and carries a significant safety consideration for progressive multifocal leukoencephalopathy (PML)

Policy Summary

PayerBlue Cross Blue Shield - North Carolina

PolicyNatalizumab (Tysabri) and natalizumab biosimilar (Tyruko) coverage

Policy CodePolicy N/A

Change TypeCriteria revised and added (Crohn's disease allowancebiosimilar addedcoding updates)

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and submit medical record documentation demonstrating diagnosis, symptom evidence and objective inflammation or prior biologic benefit as applicable.

SourceLink

On This Page

Steroid dependence or refractory: c. Corticosteroid‑dependence or refractory to oral corticosteroids.

Established biologic benefit (policy change): d. Patient is currently established on an FDA‑approved biologic or systemic immunomodulator for CD (excluding sample use) with documented positive clinical benefit (added allowance effective 7/1/2026).

Prior biologic trial or exceptions: 4. ONE of: tried and had inadequate response to ≥1 listed biologic used ≥3 months OR intolerance/hypersensitivity to ≥1 biologic OR FDA‑labeled contraindication to ALL biologics (medical record documentation required).

Combination therapy exclusion: 5. Patient is NOT receiving the requested agent in combination with another immunomodulatory or immunosuppressant agent (e.g., TNF‑alpha inhibitors, JAK inhibitors, IL‑4 inhibitors, 6‑mercaptopurine, azathioprine, cyclosporine, methotrexate).

Prescriber and program requirements CD: 6. Prescriber is a specialist for the diagnosis or has consulted a specialist; AND 7. Prescriber is registered through the CD TOUCH® or applicable REMS program.

Quantity and site of care CD: 8. Requested quantity does not exceed maximum units allowed for the duration of approval; AND 9. Site of care criteria applies for inpatient or outpatient infusion requests.

Quantity and site of care continuation: 6. Requested quantity does not exceed maximum units allowed for the duration of approval; AND 7. Site of care criteria applies for inpatient or outpatient infusion requests.

HCPCS codes associated

J2323 (Tysabri) and Q5134 (Tyruko) referenced in dosing/label tables

The patient has an intolerance or hypersensitivity to ONE of the above agents, with documentation; OR

The patient has an FDA-labeled contraindication to ALL of the above agents, with documentation; OR

The patient has been treated with at least three MS agents from different drug classes (medical record documentation required).

Documentation Required
Required Supporting Documentation
Medical record documentation must be submitted to support the diagnosis, disease activity, prior therapy attempts or contraindications, and objective findings of disease activity.
Diagnosis of relapsing form of MS (including clinically isolated syndrome, relapsing-remitting, or active secondary progressive) and patient age (≥18 years) must be documented.
Functional status documentation (ability to ambulate a few steps or functional arm/hand use for ADLs).
For highly active disease: documentation of ≥2 relapses in the prior year AND either ≥1 gadolinium-enhancing lesion on MRI or significant increase in T2 lesion load compared with prior MRI.
Documentation of prior therapies tried, dates of treatment, clinical response, intolerances/hypersensitivity, or FDA-labeled contraindications.
If applicable, documentation that the patient has been treated with at least three MS agents from different drug classes (include agent names and treatment dates).
For Crohn’s disease indications (if relevant to request), documentation of symptoms consistent with active disease and objective evidence of inflammation (imaging, endoscopy, or biomarkers) as specified in policy.

Denial Risk
Denial Triggers for Unmet Criteria
Requests will be denied if required criteria or documentation are missing, if prior therapy requirements are not met, or if disallowed combinations/age/diagnosis exclusions apply.
Missing or insufficient medical record documentation to support diagnosis, disease activity, functional status, or objective findings (e.g., MRI reports, documentation of relapses).
Failure to document trial and inadequate response to required prior MS agents, intolerance/hypersensitivity, or FDA contraindication as outlined in the prior therapy requirements.
Concurrent use of two or more disease‑modifying therapies for MS (policy disallows concurrent therapy with two or more listed agents).
Patient does not meet age requirement (e.g., under 18 for MS indication when policy requires ≥18).
Requested agent being used in combination with excluded immunomodulatory or immunosuppressant agents contrary to policy (for CD or other indications).
Prescriber not a specialist or lacking documented specialist consultation, or prescriber not enrolled in required REMS/TOUCH programs when applicable.

Significant extent/upper GI involvement on imaging or endoscopy (e.g., large/deep ulcers, fistulas, abscess, strictures, extensive disease >40 cm ileal involvement or pancolitis), corticosteroid-dependence, or refractory disease may also define moderately to severely active disease.

Established-on-biologic allowance (policy change)Policy allows patients currently established on an FDA‑approved biologic or systemic immunomodulator with documented clinical benefit to qualify (effective 7/1/2026).